Recently, Prof. WU Zhengyan from the Hefei Institutes of Physical Science, Chinese Academy of Sciences, in collaboration with Prof. ZHANG Guilong from Binzhou Medical University, has developed an innovative nano-immune agonist that significantly improves immunotherapy outcomes for melanoma—a highly aggressive and hard-to-treat form of skin cancer.
HFIPS facilities enable scientific research to address world’s challenges.
